Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- GPR 18 G ?i o ?q 11 RvD2 D 2 proinflammatory NAGl-y arachidonoylglycine PUFA
- Product Overview:
GPR18 is a G protein-coupled receptor (GPCR) that is expressed in lymphoid tissues, lung, brain, testis, and ovaries.{48187} It is coupled to the G?i/o and G?q/11 transduction pathways and is activated by the polyunsaturated fatty acid metabolite resolvin D2 (Item No. 10007279) and the endocannabinoid arachidonoyl glycine (NAGly; Item No. 90051). Resolvin D2-induced activation of GPR18 reduces inflammatory pain induced by formalin, carrageenan, and complete Freund’s adjuvant (CFA) in rats and reduces production of pro-inflammatory cytokines in mouse models of cecal ligation and puncture-induced sepsis, ocular infections, and ischemic injury.{42687,48188} NAGly-induced activation of GPR18 lowers intraocular pressure (IOP) in mice in a fatty acid amide hydrolase-dependent manner.{48189} GPR18 is also overexpressed and constitutively active in patient-derived metastatic melanoma tumor samples.{48190} Cayman’s GPR18 (C-Term) Polyclonal Antibody can be used for ELISA and immunohistochemistry (IHC) applications. The antibody recognizes the C-terminal region of GPR18 from human samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.